Healio
Edinburgh researchers say known risk factors account for no more than half the drop in heart disease, and Helen Colhoun calls it a cardiovascular drug.
Recap by typeshit. Full story at Healio.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short teaser from a Medical Update interview on how much of the weight lost on GLP-1 drugs is muscle. The full talk is on their podcast.
Several studies at the 2026 ASCO Annual Meeting examined how GLP-1 medications and weight loss relate to breast cancer risk. These are associations, not proof of cause.
Loading…